Cat.#: ASSD-141
Description | MTT is a tetrazolium dye that is frequently employed in experiments to measure the rate of cell proliferation or growth. When MTT is introduced into living cells, it undergoes a chemical transformation facilitated by certain enzymes called NAD(P)H-dependent cellular oxidoreductases, leading to the production of formazan which is a bluish or purplish insoluble substance. |
Synonyms | Thiazolyl blue tetrazolium bromide |
Size | 500 mg, 1 g |
Applications | For used quantitation of cell viability and cell proliferation where the color intensity can be measured colormetrically (at 540 or 570 nM). |
Chemical Name | 3-(4,5-dimethyl-1,3-thiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide |
Molecule Weight | 414.32 |
Molecular formula | C18H16N5SBr |
CAS Number | 298-93-1 |
PubChem identifier | 64965 |
MDL Number | MFCD00011964 |
Purity | >97% |
Solubility | Soluble in water (5 mg/ml) |
Storage | Store at -20° C |
Shipping | Shipped at 4°C |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-114 | Acridine Orange hydrochloride (AC114) | 50 mg | inquiry |
ASSD-201 | Fluoresceinamine Hydrochloride Isomer 1 (AC201) | 2 g | inquiry |
ASSD-120 | Fluorescent adenosine antagonist [XAC] (AC120) | 500 μg | inquiry |
ASSD-222 | Antifade Fluorescence Mounting Medium with Propidium Iodide (hard set) (AC222) | 10 mL | inquiry |
ASSD-121 | Fluorescent adenosine A3 antagonist [XAC] (AC121) | 500 μg | inquiry |
ASSD-139 | Adenosine A1AR Affinity-Based Probe (AfBP) (AC139) | 50 μg | inquiry |
ASSD-209 | Tetramethylrhodamine isothiocyanate Isomer R (AC209) | 5 mg, 10 mg | inquiry |
ASSD-142 | Methoxy-X04 (AC142) | 10 mg, 50 mg | inquiry |
ASSD-136 | LUF7445/A2A antagonist (AC136) | 50 μg | inquiry |
ASSD-135 | JC-1 (AC135) | 5 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.